FDA Class II Recall: PAYLESS COMPOUNDERS' Semaglutide Injectable Faces Sterility Assurance Deficiencies
PAYLESS COMPOUNDERS, LLC has initiated a Class II recall for 91 vials of its Semaglutide-Glycine-Cyanocobalamin Injectable due to a lack of sterility assurance. This event underscores critical supply chain and regulatory risks for procurement, regulatory affairs, and business development executives sourcing compounded sterile products, demanding immediate review of supplier qualification protocols.
FDA Identifies Critical Sterility Assurance Lapses at PAYLESS COMPOUNDERS
PAYLESS COMPOUNDERS, LLC, operating from Beaverton, Oregon, has initiated a Class II recall (D-0471-2026) for its Semaglutide-Glycine-Cyanocobalamin Injectable. The recall, voluntarily initiated by the firm on March 6, 2026, and classified by the FDA on April 13, 2026, specifically targets 91 vials from Lot Number 01-27-2026@14S.5. The critical reason cited for this action is a “Lack of Assurance of Sterility.” This directly impacts product safety, as injectable medications must be sterile to prevent serious infections in patients. For procurement directors and supply chain VPs, this event signals an immediate need to scrutinize all current and prospective contracts with compounding pharmacies, especially those supplying sterile products. The risk of non-sterile injectables extends beyond regulatory non-compliance to severe patient harm, including sepsis and other life-threatening complications, which can lead to significant liability and reputational damage for any entity involved in the supply chain. This incident underscores that even seemingly minor compliance failures in sterile manufacturing can have profound commercial and clinical repercussions, necessitating robust quality oversight from all stakeholders.
Facility Profile: PAYLESS COMPOUNDERS' Role in Compounded Injectable Supply
PAYLESS COMPOUNDERS, LLC operates from its facility located at 8505 Sw Creekside Pl Ste 110, Beaverton, OR 97008-7128, United States. This facility is responsible for compounding and distributing the recalled Semaglutide-Glycine-Cyanocobalamin Injectable, which was distributed exclusively within Oregon. The product, available in 2.5 mg, 5 mg, and 1 MG/ML concentrations in 0.5 mL vials, represents a customized formulation often sought by healthcare providers when commercial alternatives are unavailable, cost-prohibitive, or require specific patient-tailored dosages. For business development executives exploring partnerships with compounding pharmacies, this incident highlights the inherent risks associated with facilities that may not adhere to the same stringent Good Manufacturing Practices (GMP) as large-scale pharmaceutical manufacturers. While compounding pharmacies fulfill a vital niche in patient care, their smaller scale and customized production models do not exempt them from the absolute requirement for sterility assurance, particularly for parenteral products. Supply chain VPs must recognize that reliance on such localized compounding facilities, even for regional distribution, introduces specific vulnerabilities that demand enhanced due diligence and continuous monitoring of quality systems.
Supply Chain Exposure: Implications for Semaglutide Sourcing
The recall of Semaglutide-Glycine-Cyanocobalamin Injectable from PAYLESS COMPOUNDERS directly impacts healthcare providers and clinics in Oregon that rely on compounded versions of GLP-1 receptor agonists. Semaglutide, the active pharmaceutical ingredient (API), is a critical molecule widely used for diabetes management and weight loss, with branded versions (e.g., Ozempic, Wegovy) often facing supply constraints or high costs. This creates a market for compounded alternatives, which, while legal under specific conditions, carry distinct regulatory and quality risks. For procurement directors, this event necessitates an immediate audit of all compounded injectable suppliers, especially those providing GLP-1 agonists or similar high-demand, sterile products. The disruption caused by this recall means clinics must now scramble to find alternative sources for their patients, potentially leading to treatment interruptions. Regulatory affairs heads must advise their organizations on the evolving landscape of compounded medications, where the FDA is increasingly scrutinizing quality and manufacturing practices, particularly for sterile preparations. This incident underscores that the perceived cost savings or availability benefits of compounded products must be carefully weighed against the heightened regulatory and patient safety risks.
Mitigating Risk: Essential Sourcing Strategies for Compounded Sterile Products
Given the sterility assurance failure at PAYLESS COMPOUNDERS, procurement teams must immediately re-evaluate their sourcing strategies for compounded sterile products. While the Knowledge Graph does not name specific alternative suppliers for Semaglutide-Glycine-Cyanocobalamin Injectable, the principles for mitigating risk remain universal. Organizations should implement a multi-pronged approach to supplier qualification: first, demand comprehensive audit reports, including those from third-party auditors, specifically detailing sterility testing protocols, environmental monitoring, and aseptic processing controls. Second, establish robust quality agreements that clearly define specifications, testing methodologies, batch release criteria, and recall procedures. Third, diversify your supplier base for critical compounded injectables; relying on a single compounding pharmacy, even for localized distribution, concentrates risk. Finally, regulatory affairs heads should ensure that any compounding pharmacy under consideration possesses a clean FDA inspection history and demonstrates proactive compliance with USP <797> and <800> standards, where applicable. Proactive due diligence and continuous monitoring are paramount to safeguard patient safety and maintain an uninterrupted supply chain for essential compounded medications.
Industry Context: Persistent Sterility Challenges in Compounding and Beyond
The sterility assurance failure at PAYLESS COMPOUNDERS is not an isolated incident but reflects a persistent challenge across the pharmaceutical and compounding industries. Recent parallel events highlight this trend: Essential Wellness Pharma faced a Class II recall for its Progesterone Injection due to sterility assurance deficiencies in June 2026, and Spectra Medical Devices experienced a high-severity Class II recall for Lidocaine HCl Injection for similar reasons earlier that month. These incidents collectively signal that the FDA maintains a vigilant focus on the sterility of injectable products, regardless of the scale or nature of the manufacturing entity. For regulatory affairs heads, this pattern indicates an environment of heightened scrutiny, requiring robust internal quality management systems and continuous training on aseptic techniques. Business development executives considering market entry or expansion in areas involving sterile manufacturing, including partnerships with compounding pharmacies, must factor in the significant investment required for compliance and the potential for severe regulatory consequences if sterility protocols are compromised. This ongoing enforcement trend underscores that foundational quality control, particularly for sterile products, remains a non-negotiable aspect of market access and operational continuity.
Remediation Timeline and Anticipated Regulatory Actions
The recall of Semaglutide-Glycine-Cyanocobalamin Injectable by PAYLESS COMPOUNDERS, LLC is currently classified as 'Ongoing.' This status indicates that the firm is actively engaged in removing the affected 91 vials from distribution in Oregon and notifying customers. As a voluntary, firm-initiated recall, it demonstrates PAYLESS COMPOUNDERS' recognition of the sterility assurance deficiency. However, the FDA will closely monitor the effectiveness of this recall and the firm's subsequent corrective and preventive actions (CAPA). For regulatory affairs heads, this means anticipating a thorough FDA investigation into the root cause of the sterility failure, which could range from environmental controls to aseptic processing techniques or raw material quality. Failure by PAYLESS COMPOUNDERS to adequately identify and remediate these issues could lead to further enforcement actions, including potential Warning Letters, injunctions, or even facility closure, severely impacting their ability to operate. Procurement directors should prepare for potential long-term supply disruptions from this specific source and ensure their contingency plans for compounded injectables are robust, considering the potential for prolonged regulatory oversight and remediation timelines.